Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 158

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 158
---
 a key translational roadmap for us to prioritize compounds for further evaluation. We believe the model allows us to determine the target exposure needed to achieve a desired level of clinical activity, such 
 as the level of improvement in a patient’s forced expiratory volume in one second (“FEV1”), a measure of lung function, and sweat chloride level, the clinical biomarker of CFTR                                                                          
 function. We intend to invest in research activities and leverage insights from the model in our pursuit of delivering additional differentiated product candidates that meaningfully impact the lives of CF patients and facilitate our company’s        
 long-term growth. We also intend to opportunistically consider strategic in-licensing opportunities to maximize the value of our pipeline.                                                                                                                |

Our Company’s History and Our Team Sionna was founded in 2019 to continue to explore novel approaches to treating CF by targeting NBD1. Our co-founders,Greg Hurlbut, Ph.D., and Mark Munson, Ph.D., spent over a decade extensively researching the NBD1 target as research leaders at Sanofi SA (f/k/a Sanofi Genzyme) (“Sanofi”). Dr. Hurlbut served as Head of Protein Conformational Diseases and Rare Pulmonary 115

Diseases Research, where he led a novel strategy focused on discovering small molecules that correct the F508del CFTR mutation. Dr. Munson served as U.S. Head of Medicinal Chemistry and oversaw a diverse group of scientists that advanced multiple development candidates in oncology and rare disease. Shortly after our inception, we entered into an exclusive license agreement with Sanofi to acquire exclusive worldwide rights to research, develop and commercialize certain compounds designed to stabilize NBD1, as well as an ICL4 corrector. In addition, we have assembled a leadership team with deep expertise in drug discovery and developing CF and other rare disease therapies, launching and commercializing therapeutics globally, and building successful public pharmaceutical companies.

| • |     | Mike Cloonan, our President and Chief Executive Officer, has more than 20 years of leadership experience at                                                             
 global organizations, most recently as Chief Operating Officer at Sage Therapeutics, Inc. and prior to that as Senior Vice President of U.S. Commercial at Biogen, Inc. |

| • |     | Charlotte McKee, M.D., our Chief Medical Officer, is a pulmonologist with more than 20 years of drug                                                                                                                                      
 development experience who, while serving as Vice President of CF and Alpha-1 Antitry